We expect to
benefit from a higher level
of new generic introductions in the fourth quarter versus a year ago, including the third quarter launches
of generic versions
of Lexapro, SEROQUEL and PLAVIX; we will have some cost associated with the Alliance Boots transaction, the
magnitude of which in part will be determined by the
actual closing date
of the first step.